At the 2026 American Society of Clinical Oncology (ASCO) meeting in Chicago, Abbott unveiled clinical data that could redefine the standard of care for triple-negative breast cancer (TNBC). By leveraging a prospective sub-study of the Cambridge University Hospitals NHS Foundation Trust’s PARTNER trial, Abbott has demonstrated that minimal residual disease (MRD) testing—specifically through circulating tumour DNA (ctDNA) analysis—serves as a highly accurate prognostic tool for identifying patients at high risk of distant recurrence.
As oncology moves toward a more personalized, data-driven paradigm, these findings offer a glimpse into a future where treatment pathways are no longer dictated by population-wide averages, but by the specific molecular profile of an individual’s malignancy.
The Core Innovation: MRD Testing in TNBC
Triple-negative breast cancer is notoriously aggressive and prone to early recurrence. Historically, clinicians have struggled to determine which patients have successfully cleared all malignant cells following neoadjuvant chemotherapy (NAC) and surgery, and which patients harbor sub-clinical populations of cancer cells that remain undetected by traditional imaging modalities.
Abbott’s research addresses this "blind spot." By utilizing tumor-informed MRD assays, the company has proven that ctDNA analysis can detect the presence of residual cancer cells at the molecular level, long before they manifest as metastatic disease on a CT scan or MRI.
Chronology of the PARTNER Sub-study
The study’s design was meticulously structured to track the biological evolution of TNBC throughout the treatment journey. Patients enrolled in the PARTNER trial (NCT03150576) provided serial blood samples at six critical junctures:
- Baseline: Prior to the commencement of neoadjuvant chemotherapy.
- Mid-NAC: To assess early molecular response to treatment.
- Post-NAC: To evaluate the immediate impact of chemotherapy on ctDNA levels.
- Two to Four Weeks Post-Op: A critical window to assess if surgery successfully cleared the primary tumor and surrounding micro-environment.
- Three Months Post-Op: An early surveillance check.
- 12 Months Post-Op: Long-term follow-up to correlate molecular status with clinical outcomes.
Through the Personalised Breast Cancer Programme, Abbott received both germline and somatic DNA samples, allowing for a comprehensive, tumor-informed approach to ctDNA tracking.
Supporting Data: The Power of Sequencing
Abbott’s analytical strategy involved two distinct testing modalities inherited following its $21 billion acquisition of Exact Sciences in March 2026: Whole-Exome Sequencing (WES) and Whole-Genome Sequencing (WGS).
WES-based MRD Assays
In the WES cohort, the median assay panel size was 159 variants. The diagnostic power was significant:
- Baseline detection: 91% (50 of 55 patients).
- Post-NAC status: 4 of 63 patients showed detectable ctDNA.
- Clinical correlation: Within a median follow-up of five years, 13.1% of patients (eight individuals) experienced distant recurrences.
The data confirms that post-operative ctDNA detection via WES is "highly prognostic," serving as a definitive molecular flag for potential recurrence.
WGS-based MRD Assays
The WGS cohort, utilizing a larger median panel size of 2,962 variants, demonstrated even higher sensitivity for baseline detection, identifying ctDNA in 98% of the study population (46 of 47 patients). This suggests that while WES is an excellent prognostic tool for post-surgical monitoring, WGS may offer superior baseline characterization, providing a broader molecular map to track the cancer’s evolution throughout the treatment course.
Perspectives from Leadership: Dr. Rick Baehner
In an exclusive commentary for Medical Device Network, Dr. Rick Baehner, Chief Medical Officer of Precision Oncology at Abbott, emphasized that this data represents more than just a successful trial—it marks a fundamental shift in the cancer patient’s journey.
"Through our PARTNER study specifically, we’re seeing the potential for next-generation MRD testing to help identify recurrence risk earlier and provide more personalized insight after treatment," Dr. Baehner stated.
He further contextualized the broader vision for the company: "At the same time, advances in multi-cancer early detection are helping move cancer diagnosis further upstream, with the goal of finding cancer before symptoms appear. As these technologies continue to mature and gain adoption, we believe they have the potential to fundamentally shift cancer care toward earlier detection, earlier intervention, and more personalized management throughout a patient’s journey."
Clinical and Economic Implications
The validation of MRD testing carries profound implications for both the clinical workflow and the economics of oncology.
1. Tailored Therapeutic Intervention
If a patient tests positive for MRD post-surgery, oncologists may consider aggressive adjuvant therapies, such as enrollment in clinical trials for novel immunotherapies or targeted agents. Conversely, patients who consistently test negative for ctDNA might be candidates for "de-escalation" strategies—reducing the intensity of follow-up treatments to spare them from the toxicity of unnecessary chemotherapy.
2. The Competitive Landscape
Abbott is not alone in identifying MRD as the "holy grail" of modern diagnostics. The sector is currently experiencing a wave of consolidation. Notably, Roche subsidiary Foundation Medicine acquired Saga Diagnostics in a $595 million deal in April 2026. Dan Malarek, CEO of Foundation Medicine, has publicly categorized MRD testing as one of the most rapidly expanding sub-sectors within the broader diagnostics market.
3. Improving Patient Quality of Life
The anxiety associated with the "wait and see" period after breast cancer surgery is immense. By providing objective molecular data, clinicians can offer patients a clearer picture of their recurrence risk. This transparency empowers patients to make informed decisions about their post-treatment life, while also reducing the psychological burden of uncertainty.
Conclusion: A New Standard for Cancer Care
The data presented at ASCO 2026 provides a robust framework for integrating ctDNA analysis into routine clinical practice. By distinguishing between patients who are truly "clear" and those who require further intervention, Abbott’s WES and WGS assays offer a sophisticated toolset for the era of precision medicine.
As these diagnostic technologies mature, the goal is to shift cancer care from reactive—treating disease once it has reached a symptomatic, often metastatic stage—to proactive, monitoring patients at the molecular level to intervene before the disease takes hold. The success of the PARTNER sub-study is a landmark event, signaling that the future of oncology is being written in the blood of the patients themselves.
The industry will be watching closely as these assays move from clinical trials into widespread diagnostic adoption, potentially turning the tide in the battle against one of the world’s most challenging oncological conditions.
About the Author
